# Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression

Source: https://onco.cc/trials/nct07809906/  
OnCo record `nct07809906` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of ORM-1153 run by Orum Therapeutics USA, Inc., now recruiting.

## Summary

Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression is a phase 1 interventional study registered as NCT07809906 by Orum Therapeutics USA, Inc., with 42 participants planned, started 2026-09-23. Conditions recorded: CD123+ Acute Myeloid Leukemia. Interventions recorded: ORM-1153.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07809906
- Phase: 1
- Setting: Phase 1 First-in-Human Multi-Region Clinical Trial of ORM-1153 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Other Hematological Malignancies With CD123 Expression
- Sponsor: Orum Therapeutics USA, Inc.
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT07809906: https://clinicaltrials.gov/study/NCT07809906

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [ORM-1153](https://onco.cc/drugs/orm-1153/)
- companies: [Orum Therapeutics](https://onco.cc/companies/orum-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07809906.json